Epidarex Capital

About

Epidarex Venture Capital Skip to content EPIDAREX IS A TRANSATLANTIC VENTURE CAPITAL FIRM LED BY A DIVERSE TEAM OF EARLY-STAGE INVESTORS BUILDING BREAKTHROUGH LIFE SCIENCE COMPANIES IN EMERGING HUBS We are trusted partners to our founders and co-investors. We use our deep scientific and industry networks to create exceptional value and shared success. Epidarex builds the extraordinary. VIEW MORE ABOUT US Recent News NodThera Announces the Publication and Presentation of Cardiometabolic Clinical DataSupporting the Potential of Ruvonoflast to Treat Inflammation at the Source Data published in the Journal of the American College of Cardiology Represents first peer-reviewed publication of clinical data demonstrating reductions in cardiometabolic risk Read » NodThera Announces Late-Breaking Oral Presentation at the 94th EAS Congress Boston, MA, May 19, 2026 – NodThera, the leading clinical-stage NLRP3 company developing a portfolio of potentially best-in-class brain-penetrant oral NLRP3 inhibitors to Read » View all news About Us Epidarex Skip to content Epidarex invests in early-stage, high growth life science and health technology companies in emerging and under-ventured research hubs within the UK and US Epidarex Provides Equity Capital to Start-Ups, Including University Spin-outs Through our deep scientific and industry network we are able to identify transformative life science investments in under-ventured regions of the US and UK, building companies from scratch to create v

Key Contact

Geographic Focus